Abu Dhabi: The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, a prominent research-driven pharmaceutical company. This strategic partnership is designed to advance scientific research and innovation, foster groundbreaking research and development, and cultivate an environment of scientific excellence, further establishing the emirate as the MENA region's premier hub for healthcare, life sciences, and innovation.
According to Emirates News Agency, the agreement was signed during the BIO International Convention in Boston, at the Abu Dhabi Pavilion, by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH, and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at Boehringer Ingelheim. The signing took place in the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at Boehringer Ingelheim.
The strategic partnership aims to strengthen the Emirate's research ecosystem by facilitating access to Boehringer Ingelheim's OpnME platform. Through this platform, researchers, scientists, and innovators across Abu Dhabi will be able to leverage cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery.
OpnME offers four flagship programs: Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e), and opnTALENTS (o25). These programs provide the research community with access to advanced compounds, collaborative opportunities, expert networks, and support for emerging talent. The platform connects visionary researchers to champion research-driven medical innovation for future generations.
Dr. Asma Al Mannaei expressed that the partnership with Boehringer Ingelheim demonstrates a commitment to pioneering innovation and scientific research as part of efforts to advance health outcomes and improve the quality of life for communities globally. She highlighted the opnMe platform's role in empowering Abu Dhabi researchers by offering top-tier pharmaceutical compounds and fostering collaboration.
Ousama Alhaj emphasized Boehringer Ingelheim's pride in partnering with the Department of Health - Abu Dhabi to empower the scientific community through the OpnMe platform. He noted that this collaboration supports research, innovation, and the development of the next generation of researchers in the region.